Takeaways: Optimi Health’s plan to start a Health Canada‑authorized Phase 3 trial of synthetic MDMA‑assisted therapy for PTSD in 2027 positions the company to potentially become an early mover i...
Takeaways: Optimi Health’s plan to start a Health Canada‑authorized Phase 3 trial of synthetic MDMA‑assisted therapy for PTSD in 2027 positions the company to potentially become an early mover i...